Key Takeaways
- Strong top line, margin squeeze: Consolidated revenue grew 30% YoY to ₹496.3 crores, but EBITDA margin compressed to 14.6% as API cost increases could not be passed through swiftly enough in export markets.
- Jammu facility is the growth engine: The plant hit a ₹450 crore annualized run-rate, completed marquee customer audits, and is expected to accelerate to ₹140–150 crores per quarter in the near term.
- Export pass-through lag is the margin culprit: A 2.8% consolidated gross margin hit stemmed from longer-duration international purchase orders that delay pricing transfers, while standalone margins saw only a 0.8% impact because shorter cycles allow swifter adjustment.
- 20% volume growth model intact for two years: Management sees existing efforts sustaining the trajectory through FY29, with a ₹400 crore treasury available for greenfield or inorganic moves to fuel growth beyond that.
- What to watch next quarter: Whether API prices stabilize so margins normalize, the pace of Jammu’s ramp toward the ₹500 crore annual target, and any tangible signal on the acquisition pipeline for post-FY29 growth.
Jammu Facility Ramp-Up
- Production milestone: The facility started production in January 2025 and has now completed six quarters of operations, reaching an annualized revenue base of ₹450 crores.
- Customer validation done: Key marquee customer audits were successfully completed and onboarding of those customers is now finished, setting the stage for accelerated revenue in coming quarters.
- Near-term trajectory: Revenue is expected in the ₹140–150 crores per quarter range over the next two quarters, up from ₹105 crores this quarter, driven by customers with long gestation periods now coming online.
- Full-year target: Jammu revenue is expected to reach ₹450 crores to ₹500-plus crores this fiscal year.
- Runway: The facility has roughly two years of room to grow, with a potential to reach ₹1,200–1,300 crores.
- Margin contribution: Jammu contributed EBITDA of around ₹2 crores to ₹2.25 crores this quarter, still in early-stage ramp.
- FATR trend: Management noted that rising equipment costs tied to regulatory compliance and quality assurance are pushing asset turnover toward 3x over a four-to-five-year horizon, down from historical levels.
Vinay Lohariwala: "So whereas the cost of equipment is increasing, they are giving a better quality assurance and operational excellency as well. So that's the optimization in both the front. With the regulatory compliances, the cost of equipment, cost of plant is increasing. So that is tending towards three times of the FATR after four or five years."
Margin Dynamics & API Pass-Through
- The core problem: Consolidated gross margin was impacted by 2.8%, while standalone gross margin saw only a 0.8% hit, because domestic purchase order cycles are shorter and pricing transfers happen faster than in export markets.
- Export lag mechanics: International purchase orders are longer in duration, so when API prices rise, the transfer to customers carries a lag of certain months or a quarter, depending on PO timing and price volatility.
- Domestic agility: In domestic markets, the business cycle and PO cycle is smaller, so purchase orders get renewed swiftly and raw material price changes are transferred faster.
- No retrospective relief: Price adjustments from customers for API increases are always on a prospective, PO-to-PO basis; retrospective adjustments normally do not happen.
- Contractual protection exists: API price movements are contractually built to be passed through to customers on a long-term basis, so the margin hit is a timing issue, not a permanent loss.
- Normalization path: If API prices stabilize, margins should move back to a normalized position; management reiterated the margin will stay within a plus/minus 2% range and improvement will be organic and gradual.
- Management declined granularity: When asked which specific APIs or raw materials faced cost pressures and whether the impact was limited to certain therapeutic areas, management declined to comment, calling it a complicated mix of products, molecules, and customers.
Lokesh Bhasin: "So as I submitted, it's a complex mix, and depending upon how the pricing moved from order to order, that is then it has impacted our overall margin profile, both in slightly in domestic as well as in exports also."
Business Model & Return Profile
- Volume growth drivers: 20% volume growth is achieved through addition of new sections, new areas, and presence across regulated markets, ROTW markets, and domestic markets, not solely dependent on India volume increase.
- Ex-Jammu organic growth: The ex-Jammu portfolio (Innova, Univentis, Sharon) is growing organically at 10%–12% with margin consolidation and revenue ramp-up.
- FATR composition: Consolidated FATR ex-Jammu fell to approximately 4.0x from a historical 4.5x-plus, primarily because of the Sharon acquisition (June 2023), which operates in regulated markets with lower asset turnover; ex-Sharon standalone FATR remains 4.5x-plus.
- ROE math: With 3x FATR and 15%–16% EBITDA margin, the business model yields 16%–17% ROE with 90 days of working capital; any improvement in EBITDA margin can lift ROE to 20%.
- Growth sustainability: The 20% growth model can be maintained for the next two years easily with existing efforts from the last four to five years; momentum will continue.
- Beyond FY29: The company is evaluating both greenfield and inorganic acquisition opportunities to trigger growth beyond FY29, with a treasury of around ₹400 crores available for reinvestment and healthy debt equity.
Lokesh Bhasin: "So Abhi, if you see that the business model with the three times of the FATR and 15%, 16% of EBITDA will also result into 16%, 17% of ROE with the 90 days worth capital. It's a simple math."
CDMO & Branded Generics Performance
- CDMO momentum: CDMO revenue grew 30% YoY in Q2 and 31% in H1, driven by an expanding product portfolio, addition of new customers, and deeper engagement with existing customers.
- Branded generics traction: Branded generic revenue grew 32% YoY in Q2 and 35% in H1, supported by an expanding product portfolio and increasing market penetration.
- Export contribution: Exports contributed 29% of Q2 revenue and 30% of H1 revenue, reflecting continued progress in international market expansion.
- Strategic priorities for H2 FY27: Strengthening CDMO positioning, improving capacity utilization, expanding complex dosage forms capabilities, accelerating Jammu ramp-up, strengthening the R&D platform, and expanding branded generic presence across key markets.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jammu quarterly revenue | ₹140–150 crores per quarter | Next two quarters |
| Jammu annual revenue | Cross ₹500 crores | This fiscal year |
| Volume growth | 20% annually | Next two years (through FY29) |
| EBITDA margin range | Within plus/minus 2% of current levels | Ongoing; improvement gradual and organic |
| Margin normalization | Margins move back to normalized position if API prices stabilize | Conditional on API price stability |
| Jammu facility capacity | Reach ₹1,200–1,300 crores | Approximately two years |
| Post-FY29 growth trigger | Deploy ~₹400 crore treasury into greenfield or inorganic acquisition | To be communicated when tangible conclusion reached |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹496.3 cr, +30.5% YoY |
| H1 FY27 consolidated revenue | ₹967.2 cr, +32.1% YoY |
| EBITDA | ₹72.4 cr, +29% YoY |
| EBITDA margin | 14.6% |
| H1 FY27 EBITDA | ₹147.5 cr, +31% YoY |
| H1 FY27 EBITDA margin | 15.3% |
| PAT | ₹42.4 cr, +43% YoY |
| H1 FY27 PAT | ₹86.5 cr, +43% YoY |
| CDMO revenue | ₹345.2 cr, +30% YoY; contributed nearly 70% of total revenue |
| Branded generic revenue | ₹151.1 cr, +32% YoY |
| Exports share of revenue | 29% of Q2 revenue, 30% of H1 revenue |
| Jammu facility revenue | ~₹105 cr quarterly, annualized run-rate ~₹450 cr |
| Jammu facility capacity utilization | 22%–24% on an annualized basis |
| Jammu facility EBITDA | ~₹2 cr to ₹2.25 cr absolute |
| Consolidated gross margin impact from API cost escalation | 2.8% difference; standalone impact 0.8% |
| Ex-Jammu organic growth rate | 10%–12% |
| Volume growth guidance | 20% maintained for coming years |
| Jammu facility FY27 annual revenue expectation | ₹450 cr to ₹500+ cr |
| Jammu facility next two quarters revenue expectation | ₹125 cr to ₹150 cr per quarter |
| Consolidated FATR ex-Jammu | ~4.0x |
| FATR ex-Sharon (standalone) | 4.5x plus |
| IPM market volume growth | 6%–7% |
| Treasury available for reinvestment | ~₹400 cr |